Journal of Clinical Oncology 2025

85 papers
The 2025 edition of the Journal of Clinical Oncology features 85 papers focused on combination therapies, precision diagnostics, and the integration of artificial intelligence in clinical practice. Research themes include the evaluation of immunotherapy agents such as camrelizumab and durvalumab, often combined with chemotherapy or anti-angiogenic treatments for non-small cell lung cancer and biliary tract carcinomas. Clinical trials also investigate novel bifunctional agents like retlirafusp alfa for head and neck squamous cell carcinoma and the monotherapy ABP1019A for advanced solid tumors. Prolific contributors for the year include Jorge J. Nieva, Jennifer S. Temel, and Joel W. Neal. A notable trend in this year's research is the application of computational models to oncology. Studies explore the use of multimodal machine learning to predict treatment responses in pancreatic cancer and the implementation of large language models to identify lung cancer screening eligibility. Furthermore, generative AI is utilized to facilitate querying within large oncology databases. These developments reflect an emphasis on data-driven decision-making and the refinement of biomarker analysis, such as HER2 status and plasma ctDNA concordance in gastrointestinal malignancies.

Top Research Directions

The 5 research directions with Journal of Clinical Oncology 2025 papers, ranked by paper count. Share is the fraction of the edition’s papers in the direction.

#DirectionPapersShare
1Generalizability Challenges in Small Cohort Clinical Studies11.2%
2Identifying Rare Driver Mutations in Cancer Genomes11.2%
3Open-Label Bias in Clinical Trials11.2%
4Standardized Frameworks for Tumor Response Assessment11.2%
5The Non-Additive Toxicity of Multi-Modal Adjunctive Therapies11.2%

Download all directions as CSV

About this data

Papers. Journal of Clinical Oncology 2025 lists 85 papers on Lacuna, duplicate versions counted once; rejected and withdrawn submissions are left out.

Directions. Directions are Lacuna’s clustering of the concept elements extracted from each paper, so a paper can belong to several and direction counts add up to more than the paper count. A direction’s share is its papers divided by the edition’s papers.

Data. Counts come from Lacuna’s data build of 2026-11-20 and change as papers are added. Tables as CSV: directions. Cite as: Lacuna, “Journal of Clinical Oncology 2025”, https://lacuna.tiptreesystems.com/venue/journal-of-clinical-oncology/2025.

Top Authors

AuthorPapers
Jorge J. Nieva3
Jiang Bian2
Alexander Baras1
Amanda S Barnard1
Andreas Kleppe1
Baris Turkbey1
Benjamin Haibe-Kains1
Bradford J Wood1
Jakob Nikolas Kather1
Jeremy Yuen-Chun Teoh1
Jingchuan Guo1
Jinxi Xiang1
Jitesh Joshi1
Julian C. Hong1
Kui Jiang1
Rahul G Krishnan1
Yuming Jiang1
Zhijie Liu1
Zongliang Ji1

Papers

Title
A 20-year population-wide cohort study on association of aspirin and risk of gastrointestinal and non-gastrointestinal cancer.
A first-in-human phase 1 study of LY3866288 (LOXO-435), a potent, highly isoform-selective FGFR3 inhibitor (FGFR3i) in advanced solid tumors with FGFR3 alterations: Initial results from FORAGER
Age acceleration among adolescent and young adult patients with Ewing sarcoma and osteosarcoma.
Aiding data retrieval in clinical trials with large language models: The APOLLO 11 Consortium in advanced lung cancer patients.
AI-driven reflectance confocal microscopy for noninvasive diagnosis and accurate surgical margin assessment intra-operatively in oral cavity squamous cell carcinoma.
A large language model (LLM)-based multi-agent framework for risk stratification and treatment recommendations in localized prostate cancer (locPCa).
Amivantamab Plus Lazertinib in Atypical EGFR -Mutated Advanced Non–Small Cell Lung Cancer: Results From CHRYSALIS-2
A multicenter, prospective, non-interventional study to investigate the treatment patterns of neratinib in human epidermal growth factor receptor 2 positive (HER2+) early breast cancer (EBC) in China:
A novel computational approach for survival prediction via fusion of whole-slide images and clinical data.
A novel virtual reality supportive care intervention (BMT-VR) for patients undergoing hematopoietic stem cell transplantation (HSCT): A pilot randomized clinical trial.
A phase 1/2 trial of durvalumab plus intravesical gemcitabine and docetaxel in BCG-unresponsive non-muscle invasive bladder cancer patients (HCRN GU16-243: ADAPT-BLADDER Cohort 4).
A phase I clinical trial of ABP1019A monotherapy in patients with advanced malignant solid tumors.
A phase I trial of intratumoral adenovirus-interleukin-12 (IT-ADV/IL-12) and atezolizumab in metastatic non-small cell lung cancer (NSCLC) progressed on first-line immunotherapy.
Association of glucagon-like peptide 1 receptor agonists with cancer risk in obesity adults with and without diabetes: A target trial emulation study.
Automated Lymph Node and Extranodal Extension Assessment Improves Risk Stratification in Oropharyngeal Carcinoma
Automated risk stratification in localized prostate cancer using an AI-assisted framework.
Bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 plus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): Survival results of a phase II trial.
Blended survivorship and palliative care for patients with advanced lung cancer receiving targeted therapy: An open pilot.
Camrelizumab combined with 2 cycles of chemotherapy as first-line treatment for advanced non-small cell lung cancer (NSCLC): A two-arm, single-center, phase 2 study.
Camrelizumab combined with rivoceranib and TACE in the perioperative treatment of hepatocellular carcinoma: A randomized, open-label multicenter trial.
Caution in Interpreting NOTCH1 Mutation as a Predictive Biomarker of Tislelizumab Response in Esophageal Squamous Cell Carcinoma
Cervical cancer mortality trends and disparities in women of the United States: A two-decade retrospective analysis.
Characterizing health related quality of life among individuals living with non-small cell lung in the United States: Findings from the Cancer Experience Registry.
Clinical large language model to predict loss to follow up for oncology patients discharged to skilled nursing facilities.
Clinical study on splenic radiation dose constraints.
Codon 167 missense mutations in von Hippel-Lindau syndrome: Genotype-phenotype correlations in a population-based study.
Cohort builder in Tempus Lens: Querying a large oncology database with generative AI.
Combination of mitoxantrone hydrochloride liposome with tislelizumab in patients with relapsed or refractory NK/T cell lymphoma: A phase Ib/II study.
Combined treatment of durvalumab, bevacizumab and tremelimumab in subjects with hepatocellular carcinoma (HCC) or biliary tract carcinoma (BTC).
Complementary value of a digital pathology biomarker to post-surgery circulating tumor DNA in risk stratification of stage III colon cancer patients receiving adjuvant chemotherapy.
Concordance analysis between tumor tissue HER2 status by immunohistochemistry (IHC) and in situ hybridization (ISH) and a translational analysis of plasma ctDNA in patients (pts) with biliary tract ca
Dendritic cell–based vaccines (KSD-101) against EBV-associated lymphoproliferative diseases: Results from an ongoing phase I clinical study.
Development and validation of a proteo-metabolic panel for detection of asymptomatic ovarian cancer with minimal serum sample requirements: A multi-center prospective study.
Digital pathology–based AI spatial biomarker to predict outcomes for immune checkpoint inhibitors in advanced non-small cell lung cancer.
Early detection of ovarian cancer: An accurate high-throughput extracellular vesicle test.
Effect of clonal competition model of PDAC liver metastasis on a pan-carcinoma gene signature of metastatic potential.
Efficacy and safety of neoadjuvant zimberelimab and cetuximab plus nab-paclitaxel and cisplatin (NeoZCPC) for resectable locally advanced hypopharyngeal/laryngeal squamous cell carcinoma: An open-labe
Efficacy and safety of sacituzumab tirumotecan monotherapy in patients with advanced urothelial carcinoma who progressed on or after prior anti-cancer therapies: Report from the phase 1/2 MK-2870-001
Efficacy of IFN-alpha-2b as adjuvant treatment for acral melanoma: A retrospective analysis of 113 cases in China.
Enabling national identification of lung cancer screening eligibility with large language models.
First-line durvalumab with arterial chemotherapy in major portal invaded hepatocellular carcinoma: The phase 2 DurHope study with biomolecular analyses.
First preliminary results of artificial intelligence-generated, explainable treatment recommendations for renal cell cancer based on multidisciplinary cancer conferences.
Foundation Model for Predicting Prognosis and Adjuvant Therapy Benefit From Digital Pathology in GI Cancers
Geographic and demographic disparities in lung cancer prevalence among young adults: A SEER-based analysis.
GPRC5D and BCMA bi-specific CAR-T: Ex vivo study to simulate early to late-line multiple myeloma (MM) with elevated soluble BCMA.
Hypoxia-responsive CEA CAR-T cells therapy for relapsed or refractory non-small cell lung cancer: A single-arm, open-label, phase I trial.
IBI354, an anti-HER2 antibody-drug conjugate, in patients with locally advanced unresectable or metastatic ovarian cancers: Updated results from a phase I trial.
Impact of declining renal function on bladder cancer (BC) mortality in the U.S. (1999-2023): A regression analysis using the CDC WONDER database.
Impact of HER2-ultralow heterogeneity and optimal threshold on trastuzumab deruxtecan (T-DXd) efficacy in metastatic breast cancer: A national multicenter cohort study (HEROIC).
Improving prostate cancer risk stratification using spatial single-cell tumor profiling.

Page 1/2 next »